We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

January 27, 2021

This is the Future of Digital Therapeutics

Reports
HealthXL Research Team
&
Brian Dolan

Sneak peek into our upcoming report

We are excited to give you a sneak peek into our upcoming report on Prescription Digital Therapeutics. 

In 2018, we released our first report on Digital Therapeutics (DTx), aiming to get behind the hype and dig into the DTx landscape, business models, regulation, reimbursement, evidence, and adoption. In the past two years, a lot has happened. A wide variety of companies have co-opted the term “digital therapeutics” to describe their digital health offerings. This report seeks to cut through some of that noise by focusing on a smaller subset of this group: prescription digital therapeutics (PDT).

We are excited to announce that for our 2021 PDT report, we are collaborating with Brian Dolan of Exits & Outcomes (E&O). E&O is a digital health research and media company led by Brian, who also founded MobiHealthNews back in 2008. 

The objective of this HealthXL- E&O Report is to deep dive into one subsegment of DTx that has enormous potential: prescription products. We shine a light on clinical validation, adoption, investments, reimbursement and regulation. 

This report contains key examples of PDT applications, industry implications and a critical viewpoint of the current reality of the DTx environment and those which must be addressed in order to truly deliver on the DTx promise in terms of optimized health outcomes. 

What can you expect to see? 


Investment / Solutions Landscape

We examine how the investment landscape for PDTs has changed over 2018-2020.  It is clear that COVID-19 has hugely increased investments/partnerships within the digital health space, PDTs included! The top funded PDT company of 2020 was Biofourmis, obtaining a whopping $100 million in investments.

Source: Portal.HealthXL.com


Business Models and Pricing

Business models and pricing for digital therapeutics are some of the most sought after details among large corporations, investors and startups alike. In this section of the report we outline different PDT business models which include those that follow the more traditional pharmaceutical pathways to sell their products, and newly emerging models which are leveraging telemedicine to facilitate D2C access. We also take a look at the pricing of PDTs which are currently available on the market.

Clinical and Economic Outcomes

Only 27% of PDTs have published RCTs to validate their product offerings. We compare and contrast the current frameworks that support the validation of PDTs [NICE, FDA, TGA, DIGA], and dig into the rigor of evidence provided for these products vs traditional pharmaceutical agents. We also discuss the use of digital endpoints (or lack thereof) in the validation of these products.

Regulatory Environment, Reimbursement and Prescription Pathways


The report digs deep into the regulatory environment and prescription pathways for PDTs in both the US and the EU. We also assess the reimbursement landscape for PDTs across the globe - while developments in the US remain thin, the EU and Japan appear to be leading the charge in the reimbursement space. 

Source: Portal.HealthXL.com


Adoption and Enablement

Prescription capabilities remain a key challenge in the adoption of PDTs, although Germany and Belgium are spearheading change within this space. In the report we take a deep dive into the adoption and enablement of PDTs, fleshing out regional differences and highlighting companies that are shaking up the distribution chain.


The Future of PDT

PDTs are quickly emerging as one of the most spoken about areas of digital health, although it would appear that many barriers remain for the widespread adoption of these technologies. What needs to happen in politics, within the FDA, within PBMs, in the minds of physicians and consumers to move the needle? We gaze into the crystal ball.


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Prescription DTx - the future of DTx

1st March @ 11:00am EDT

Join our Digital Health Meeting focused on Prescription DTx- the future of DTx. This is a great opportunity to listen to your peers and thought leaders in the industry while also getting involved in the discussion. Apply promptly to avoid disappointment.

Featuring
Brian Dolan
Brian Dolan
Founder/Lead Writer, Exits & Outcomes
Shwen Gwee
Shwen Gwee
VP and Head of Global Digital Strategy at Bristol Myers Squibb
Featuring
Brian Dolan
Brian Dolan
Founder/Lead Writer, Exits & Outcomes
Shwen Gwee
Shwen Gwee
VP and Head of Global Digital Strategy at Bristol Myers Squibb
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

The Power of Real-World Evidence in DTx-Pharma partnerships

3rd March @ 11:00 am EDT

Join our Digital Health Meeting as we discuss the power of RWE in DTx-Pharma partnerships. This is a great opportunity to connect with new people and listen to valuable insights from thought leaders in the industry. Apply promptly to avoid missing out.

Featuring
Aahuti Rai
Aahuti Rai
Chief Strategy & Growth Officer at Ampersand Health
Philip Russmeyer
Philip Russmeyer
Founder & CEO, FITFILE
Featuring
Aahuti Rai
Aahuti Rai
Chief Strategy & Growth Officer at Ampersand Health
Philip Russmeyer
Philip Russmeyer
Founder & CEO, FITFILE
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

DTx- Overview of the market and deals

8th March @ 10.30am EDT

Join our Digital Health Meeting as we discuss the DTx market and also the most remarkable investments and partnerships in the DTx industry in recent times. Listen, engage and enjoy.

Featuring
Dr Uzma Choudry
Dr Uzma Choudry
Venture Capital Investor, Octopus Ventures
Elan Tye
Elan Tye
Principal, JAZZ Venture Partners
Featuring
Dr Uzma Choudry
Dr Uzma Choudry
Venture Capital Investor, Octopus Ventures
Elan Tye
Elan Tye
Principal, JAZZ Venture Partners
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

How should we measure efficacy and safety of DTx products?

15th March @ 11:00am EDT

Join us as we discuss how efficacy and safety should be measured in DTx products. Apply now to interact with your peers and gain insight from thought leaders in the industry.

Featuring
Jessica Shull
Jessica Shull
European Lead, Digital Therapeutics Alliance
Jin Lee
Jin Lee
Director of Digital Health Product, Astellas
Featuring
Jessica Shull
Jessica Shull
European Lead, Digital Therapeutics Alliance
Jin Lee
Jin Lee
Director of Digital Health Product, Astellas

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery

Digital Health for Older Adults - Informal Caregivers

1st March 12:00pm EDT

Join our Digital Health Meeting as we discuss the unique opportunity for digital health companies both to support informal caregivers in the elderly healthcare management and to improve caregivers' mental health and wellness. Great opportunity to connect with peers and meet new people.

Featuring
Kerry Burnright
Kerry Burnright
Chief Gerontologist at GrandPad
Brian Kaskie
Brian Kaskie
Associate Professor, University of Iowa
Featuring
Kerry Burnright
Kerry Burnright
Chief Gerontologist at GrandPad
Brian Kaskie
Brian Kaskie
Associate Professor, University of Iowa
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Prescription DTx - the future of DTx

1st March @ 11:00am EDT

Join our Digital Health Meeting focused on Prescription DTx- the future of DTx. This is a great opportunity to listen to your peers and thought leaders in the industry while also getting involved in the discussion. Apply promptly to avoid disappointment.

Featuring
Brian Dolan
Brian Dolan
Founder/Lead Writer, Exits & Outcomes
Shwen Gwee
Shwen Gwee
VP and Head of Global Digital Strategy at Bristol Myers Squibb
Featuring
Brian Dolan
Brian Dolan
Founder/Lead Writer, Exits & Outcomes
Shwen Gwee
Shwen Gwee
VP and Head of Global Digital Strategy at Bristol Myers Squibb
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support

Conversational patient engagement – voice and chatbots

2nd March @ 10:30am EDT

Join our Digital Health meeting focused on Conversational engagement led by Keith Grimes. Apply now to get involved in the discussion.

Featuring
Keith Grimes
Keith Grimes
Clinical Innovation Director / Clinical AI Director at Babylon Health and Founder of VR Doctors
Vanessa Lemarié
Vanessa Lemarié
SVP Life Sciences & Rare Diseases, Ada Health
Featuring
Keith Grimes
Keith Grimes
Clinical Innovation Director / Clinical AI Director at Babylon Health and Founder of VR Doctors
Vanessa Lemarié
Vanessa Lemarié
SVP Life Sciences & Rare Diseases, Ada Health
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

The Power of Real-World Evidence in DTx-Pharma partnerships

3rd March @ 11:00 am EDT

Join our Digital Health Meeting as we discuss the power of RWE in DTx-Pharma partnerships. This is a great opportunity to connect with new people and listen to valuable insights from thought leaders in the industry. Apply promptly to avoid missing out.

Featuring
Aahuti Rai
Aahuti Rai
Chief Strategy & Growth Officer at Ampersand Health
Philip Russmeyer
Philip Russmeyer
Founder & CEO, FITFILE
Featuring
Aahuti Rai
Aahuti Rai
Chief Strategy & Growth Officer at Ampersand Health
Philip Russmeyer
Philip Russmeyer
Founder & CEO, FITFILE

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.